CHMP backs Novo's haemophilia A drug Frehemgo
Novo has moved a step closer to EU approval of its long-acting haemophilia A therapy, Frehemgo, which could be a future blockbuster.
Newsletters and Deep Dive digital magazine
Novo has moved a step closer to EU approval of its long-acting haemophilia A therapy, Frehemgo, which could be a future blockbuster.
The chairs of six UK parliamentary committees have asked the National Audit Office to investigate the UK-US pharma deal and its impact on the NHS.
Patients in the US with Sanfilippo syndrome type A have their first FDA-approved therapy, Ultragenyx Pharma's $3.9m one-shot gene therapy Fayuvi.
Bayer's fast-growing Kerendia has had its label extended in the US to include chronic kidney disease associated with type 1 diabetes.
Almost three years after Enhertu was made available in Scotland, the drug is finally an option for patients in England with HER2-low breast cancer.
Editor's Picks
Newsletters and Deep Dive
digital magazine